Rob Gronkowski Is “Back in The Game” with CBDMEDIC™ – InsuranceNewsNet

InsuranceNewsNet — Your Industry. One Source.™

Sign in
  • Subscribe
  • About
  • Advertise
  • Contact
Home Now reading Newswires
Topics
    • Life Insurance
    • Annuity News
    • Health/Employee Benefits
    • Property and Casualty
    • Advisor News
    • Washington Wire
    • Regulation News
    • Sponsored Content
    • Webinars
    • Monthly Focus
  • INN Exclusives
  • NewsWires
  • Magazine
  • Free Newsletters
Sign in or register to be an INNsider.
  • INN Exclusives
  • NewsWires
  • Magazine
  • Free Newsletters
  • Insider
  • About
  • Advertise
  • Editorial Staff
  • Contact
  • Newsletters

Get Social

  • Facebook
  • Twitter
  • LinkedIn
Newswires
Newswires RSS Get our newsletter
Order Prints
April 22, 2020 Newswires No comments
Share
Share
Tweet
Email

Rob Gronkowski Is “Back in The Game” with CBDMEDIC™

Business Wire

Rob Gronkowski returns to professional football with CBDMEDIC playing a key role in his recovery and comeback.

WOONSOCKET, R.I. & TORONTO--(BUSINESS WIRE)-- Abacus Health Products, Inc. (CSE: ABCS, OTCQX: ABAHF) (“Abacus” or the “Company”) today announces its support of Rob Gronkowski’s (Gronk), three-time professional football champion, decision to return to play professional football. Gronkowski partnered with Abacus following nine years of playing in New England. His relationship with Abacus is as a result of his focused effort to recover from the injuries sustained throughout his 9-season career. Following his retirement from professional football in March 2019, Rob Gronkowski announced his partnership with Abacus Health Products, the company behind CBDMEDIC topical pain relief products. In doing so, Gronkowski became an outspoken advocate for CBD in an effort to help athletes and people suffering with pain.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200422005882/en/

Rob Gronkowski returns to professional football. (Source: Abacus)

Rob Gronkowski returns to professional football. (Source: Abacus)

Gronkowski attributes his use of CBDMEDIC as a key factor in his decision to return to playing football, stating, “I left the game last year after realizing that my body had taken a beating and needed to recover. I’ve taken the recovery process seriously and CBDMEDIC has played a big role in my recovery. Now I’m glad to share that I’m back in the game!” Gronkowski added, “As a result of my personal experience I have advocated for the use of CBD products to be available to both the public and professional athletes and am glad to see changes in policy with sports organizations across the board.”

The use of CBD, an ingredient in hemp extract, in topical medications has experienced a gradual liberalization over the past years as a result of US federal government legislation, the distribution of products by major US retail chains, as well as the allowance by many professional sports leagues.

Abacus’ CBDMEDIC products contain active pharmaceutical ingredients as well as hemp extract. The 2018 Farm Bill, passed in December 2018, permanently removed hemp from the Controlled Substances Act (CSA), and as a result, hemp became an agricultural commodity governed by the U.S. Department of Agriculture (USDA). All hemp used in the manufacture and production of CBDMEDIC products is legally grown and all CBDMEDIC products are 100% THC-free and all-natural. CBDMEDIC products can be purchased over the counter by Americans coast to coast at the leading national retail pharmacy chains.

Abacus and Gronkowski have welcomed the significant changes made across professional sports over the past years that reflect the changing attitudes and awareness in the use of hemp extract and CBD to address a variety of health issues including pain management, which is a positive indicator for the future role of CBD in professional sports.

Abacus and Gronkowski have affirmed that the commercial relationship between the parties continues to be effective following Gronkowski’s decision to return to professional football.

Perry Antelman, CEO of Abacus Health Products stated, ”We look forward to continuing our relationship with Rob and supporting his advocacy efforts in raising awareness of the benefit of our CBDMEDIC topical medications to provide relief for millions of Americans. We are thrilled that Rob is back in the game. It has been an incredible year working closely with Rob - seeing him recover and get into the best shape he's ever been and to know that CBDMEDIC products have been a major part of his journey. Now that Rob has made this phenomenal comeback, he's also scored a huge win for CBD advocacy, a mission that he is dedicated to. To that end, we’re pleased he’s taking time out to help people with crippling arthritis pain in the SURVIVE & THRIVE: COVID-19 Celebrity Challenge Event in support of the Arthritis Foundation at 8pm tonight on their Facebook Live page.”

About SURVIVE & THRIVE

CBDMEDIC™ has teamed up with a cast of celebrities including 3X Pro Football Champion Rob Gronkowski, Hall of Fame Linebacker Brian Urlacher, American Ninja Warrior host Matt Iseman, Sports Illustrated Cover Model Camille Kostek, and the President of Walgreens, Richard Ashworth, for the SURIVIVE & THRIVE: COVID-19 CELEBRITY CHALLENGE in support of the Arthritis Foundation. These celebrities will face entertaining challenges on the Arthritis Foundation’s Facebook Live page at 8pm EST on April 22, 2020 in an effort to raise money for those battling social isolation during COVID-19.

#SurviveandThrive

Link to SURVIVE & THRIVE here: https://bit.ly/34LKsqC

About CBDMEDIC

Launched in 2019, CBDMEDIC offers a line of topical pain medications that combine naturally-derived pain-relieving active OTC drug ingredients with 100% natural emollients (skin softening ingredients), essential oils, and broad-spectrum THC-free, CBD-rich hemp oil to create unique formulations that work with the body for powerful, targeted, and effective pain relief.

Forward-Looking Statements

This news release contains forward-looking statements or information (collectively, "forward-looking statements") within the meaning of applicable securities legislation. Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company's control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements.

The forward-looking statements contained in this news release include, without limitation, statements relating to the execution of the Company’s growth strategy are based on management's current expectations and are subject to a number of risks, uncertainties and assumptions, including assumptions regarding the Company's ability to efficiently operate its business, market and economic conditions, business prospects or opportunities, future plans and strategies, anticipated events and trends, and regulatory changes that may affect the Company and its customers and industry. There can be no assurance that actual results will not differ materially from those expressed or implied in forward looking statements. Undue reliance should not be placed on forward-looking statements. Additional information about these risks, uncertainties and assumptions is contained under "Risk Factors and Uncertainties" in the Company's annual information form dated April 12, 2019, which is available under the Company's SEDAR profile at www.sedar.com. Each forward-looking statement speaks only as of the date hereof, and the Company undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

About Abacus Health Products, Inc.

Abacus is a company engaged in the development and commercialization of over-the-counter (OTC) registered topical medications with active pharmaceutical ingredients and which contain organic and natural ingredients, including a cannabinoid-rich hemp extract containing CBD from Cannabis sativa L plant. Abacus’ products are aimed at the rapidly growing markets for topical pain relief and therapeutic skincare and are based on proprietary patent-pending technologies developed by Abacus. Abacus’ formulations combine advanced science with organic and natural ingredients to provide safe relief. Abacus currently offers two lines of products: (i) CBD CLINIC™, marketed to the professional practitioner market, and (ii) CBDMEDIC™, marketed to the consumer market. Abacus’ products are offered across the United States and are produced by a contract manufacturer in an FDA registered and audited manufacturing facility.

To learn more about Abacus, visit www.abacushp.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20200422005882/en/

For further information:

Hank Hague, Chief Financial Officer

Email: [email protected]

Or

Bill Mitoulas, Investor Relations

Email: [email protected]

Office: 1.416.479.9547

Source: Abacus Health Products, Inc.

Older

AM Best Affirms Credit Ratings of Hamilton Re, Ltd. and Hamilton Insurance Designated Activity Company

Newer

Cartwright unveils hazard pay proposal for essential front line workers

Advisor News

  • Fidelity: retirement savers look long term, continue to save despite headwinds
  • Sometimes debt could be a helpful tool
  • Debt consolidation becomes more attractive
  • 31% of retirees say continued inflation would motivate them to rejoin the workforce
  • Inflation Reduction Act may have little impact on inflation
More Advisor News

Annuity News

  • Global Atlantic announces $10B group annuity reinsurance deal with Equitable
  • Colorado adopts new annuity sales regulations
  • National Western Life introduces new fixed indexed annuity, NWL New Frontiers
  • Jackson National announces second quarter 2022 results
  • Brighthouse Financial adds to Shield Level annuity suite with new product
More Annuity News

Health/Employee Benefits News

  • Why letting Medicare negotiate drug prices won’t be a game-changer for health care
  • America’s Essential Hospitals praise new law, urge more funding
  • Retired teachers oppose $9M in STRS Ohio pension staff bonuses
  • Higher out-of-pocket patient bills are hitting hospitals hard
  • Best’s Commentary: Inflation Reduction Act will benefit U.S. health insurers
More Health/Employee Benefits News

Life Insurance

  • Sammons names Tyler Brown new government affairs director
  • Alex Murdaugh petitions to delay Mallory Beach trial amid murder charges
  • Sales of life combination products rebound in 2021, LIMRA reports
  • Integrity Marketing Group acquires Richman Insurance Agency
  • How to get the most out of Life Insurance Awareness Month
More Life Insurance

- Presented By -

How to Write For InsuranceNewsNet

Find out how you can submit content for publishing on our website.
View Guidelines

FEATURED OFFERS

Get Linked INN to your industry Connect with INN on LinkedIn to be first on all the news and insights that matter to your industry.

Press ReleasesAll press releases

  • Ibexis Life & Annuity Insurance Company Launches Innovative Fixed Annuity
  • National Western Life introduces newest fixed indexed annuity, NWL® New Frontiers
  • CybeReady Supports Security Defenses with CISO Toolkit
  • Life and Disability Income Insurance Products from MassMutual Now Available on iPipeline®’s End-to-End Digital Platform
  • Business on the Go with The Crump Mobile App
Add your Press Release >

Topics

  • Life Insurance
  • Annuity News
  • Health/Employee Benefits
  • Property and Casualty
  • Advisor News
  • Washington Wire
  • Regulation News
  • Sponsored Content
  • Webinars
  • Monthly Focus

Top Sections

  • Life Insurance
  • Annuity News
  • Health/Employee Benefits News
  • Property and Casualty News
  • AdvisorNews
  • Washington Wire
  • Insurance Webinars

Our Company

  • About
  • Editorial Staff
  • Magazine
  • Write for INN
  • Advertise
  • Contact

Sign up for our FREE e-Newsletter!

Get breaking news, exclusive stories, and money- making insights straight into your inbox.

select Newsletter Options
Facebook Linkedin Twitter
© 2022 InsuranceNewsNet.com, Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy
  • AdvisorNews

Sign in with your INNsider Account

Not registered? Become an INNsider.